- Home
- MVST vs PHAT Comparison
MVST vs PHAT Comparison
Compare MVST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- PHAT
- Stock Information
- Founded
- MVST 2006
- PHAT 2018
- Country
- MVST United States
- PHAT United States
- Employees
- MVST N/A
- PHAT N/A
- Industry
- MVST Industrial Machinery/Components
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- PHAT Health Care
- Exchange
- MVST Nasdaq
- PHAT Nasdaq
- Market Cap
- MVST 848.0M
- PHAT 820.8M
- IPO Year
- MVST N/A
- PHAT 2019
- Fundamental
- Price
- MVST $2.56
- PHAT $12.34
- Analyst Decision
- MVST Strong Buy
- PHAT Strong Buy
- Analyst Count
- MVST 1
- PHAT 5
- Target Price
- MVST $6.00
- PHAT $16.40
- AVG Volume (30 Days)
- MVST 7.3M
- PHAT 1.1M
- Earning Date
- MVST 08-11-2025
- PHAT 11-06-2025
- Dividend Yield
- MVST N/A
- PHAT N/A
- EPS Growth
- MVST N/A
- PHAT N/A
- EPS
- MVST N/A
- PHAT N/A
- Revenue
- MVST $422,605,000.00
- PHAT $114,039,000.00
- Revenue This Year
- MVST $25.36
- PHAT $207.52
- Revenue Next Year
- MVST $30.46
- PHAT $96.46
- P/E Ratio
- MVST N/A
- PHAT N/A
- Revenue Growth
- MVST 20.84
- PHAT 1049.82
- 52 Week Low
- MVST $0.15
- PHAT $2.21
- 52 Week High
- MVST $4.72
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- MVST 40.50
- PHAT 68.51
- Support Level
- MVST $2.53
- PHAT $11.25
- Resistance Level
- MVST $2.69
- PHAT $12.96
- Average True Range (ATR)
- MVST 0.15
- PHAT 0.73
- MACD
- MVST 0.01
- PHAT 0.02
- Stochastic Oscillator
- MVST 30.00
- PHAT 80.38
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.